Pablo Campo MartÃ-nez-Lage

List of Publications by Year
in descending order

98 papers	4,879 citations	94433 37 h-index	106344 65 g-index
112 all docs	112 docs citations	112 times ranked	7798 citing authors

#	Article	IF	Citations
1	Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimerâ€™s disease CSF profile of neuronal injury and inflammation. Molecular Psychiatry, 2022, 27, 1990-1999.	7.9	9
2	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2022, 17, 27.	10.8	30
3	Genome-Wide Association Study of Alzheimerâ€™s Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimerâ€™s Disease Multimodal Biomarker Discovery Dataset. Frontiers in Aging Neuroscience, 2022, 14, 840651.	3.4	20
4	Effects of age, amyloid, sex, and APOE Îµ4 on the CSF proteome in normal cognition. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12286.	2.4	4
5	Plasma lipids are associated with white matter microstructural changes and axonal degeneration. Brain Imaging and Behavior, 2021, 15, 1043-1057.	2.1	10
6	Replication study of plasma proteins relating to Alzheimer's pathology. Alzheimer's and Dementia, 2021, 17, 1452-1464.	0.8	13
7	Accelerated longâ€term forgetting in individuals with subjective cognitive decline and amyloidâ€Î²2 positivity. International Journal of Geriatric Psychiatry, 2021, 36, 1037-1049.	2.7	6
8	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. Alzheimer's and Dementia, 2021, 17, 1628-1640.	0.8	23
9	Plasma Proteomic Biomarkers Relating to Alzheimerâ€™s Disease: A Meta-Analysis Based on Our Own Studies. Frontiers in Aging Neuroscience, 2021, 13, 712545.	3.4	16
10	CSF Proteomic Alzheimerâ€™s Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. Proteomes, 2021, 9, 36.	3.5	9
11	Therapeutic plasma exchange with albumin: a new approach to treat Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2021, 21, 843-849.	2.8	6
12	Accelerated longâ€term forgetting over three months in asymptomatic APOE É›4 carriers. Annals of Clinical and Translational Neurology, 2021, 8, 477-484.	3.7	7
13	Sex-Specific Metabolic Pathways Were Associated with Alzheimerâ€™s Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. Biomedicines, 2021, 9, 1610.	3.2	7
14	Adopting the FINGER multimodal intervention methodology to prevent cognitive decline in Southern Europe: The GOIZ ZAINDU pilot study. Alzheimer's and Dementia, 2021, 17, .	0.8	0
15	Genome-wide association study of Alzheimerâ€™s disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. Translational Psychiatry, 2020, 10, 403.	4.8	42
16	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimerâ€™s Disease Pathology. Journal of Alzheimer's Disease, 2020, 77, 1353-1368.	2.6	7
17	Economic evaluation of supplementing the diet with Souvenaid in patients with prodromal Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 166.	6.2	2
18	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimerâ€™s Disease Multimodal Biomarker Discovery Cohort. Journal of Alzheimer's Disease, 2020, 74, 213-225.	2.6	13

#	Article	IF	Citations
19	APOE Îµ4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 65.	6.2	28
20	Cerebrospinal Fluid 7-Ketocholesterol Level is Associated with Amyloid-Î²42 and White Matter Microstructure in Cognitively Healthy Adults. Journal of Alzheimer's Disease, 2020, 76, 643-656.	2.6	8
21	Worldâ€Wide FINGERS Network: A global approach to risk reduction and prevention of dementia. Alzheimer's and Dementia, 2020, 16, 1078-1094.	0.8	257
22	Pathophysiological subtypes of Alzheimerâ€™s disease based on cerebrospinal fluid proteomics. Brain, 2020, 143, 3776-3792.	7.6	89
23	PLASMA A?42/40 RATIO DETECTS EARLY STAGES OF ALZHEIMERâ€™S DISEASE AND CORRELATES WITH CSF AND NEUROIMAGING BIOMARKERS IN THE AB255 STUDY. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-8.	2.7	41
24	Localisation of oxysterols at the sub-cellular level and in biological fluids. Journal of Steroid Biochemistry and Molecular Biology, 2019, 193, 105426.	2.5	23
25	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. Alzheimer's and Dementia, 2019, 15, 1478-1488.	0.8	46
26	Early detection of subtle motor dysfunction in cognitively normal subjects with amyloid-Î² positivity. Cortex, 2019, 121, 117-124.	2.4	12
27	Tau Protein is Associated with Longitudinal Memory Decline in Cognitively Healthy Subjects with Normal Alzheimerâ€™s Disease Cerebrospinal Fluid Biomarker Levels. Journal of Alzheimer's Disease, 2019, 70, 211-225.	2.6	10
28	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. Alzheimer's and Dementia, 2019, 15, 817-827.	0.8	62
29	Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimer's and Dementia, 2019, 15, 776-787.	0.8	134
30	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. Alzheimer's and Dementia, 2019, 15, 644-654.	0.8	90
31	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. Alzheimer's and Dementia, 2019, 15, 742-753.	0.8	82
32	Mechanisms underlying resilience inÂageing. Nature Reviews Neuroscience, 2019, 20, 246-246.	10.2	34
33	A metaboliteâ€based machine learning approach to diagnose Alzheimerâ€type dementia in blood: Results from the European Medicalâ€‰Information Framework for Alzheimer disease biomarker discovery cohort. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 933-938.	3.7	70
34	Plasma AÎ²42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study. Alzheimer's Research and Therapy, 2019, 11, 96.	6.2	38
35	Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid. Molecular and Cellular Proteomics, 2019, 18, 546-560.	3.8	115
36	Isopropanol extraction for cerebrospinal fluid lipidomic profiling analysis. Talanta, 2019, 195, 619-627.	5.5	16

#	Article	IF	Citations
37	European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials. Alzheimer's and Dementia, 2018, 14, 837-842.	0.8	20
38	Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study. Alzheimer's and Dementia, 2018, 14, 280-292.	0.8	246
39	Cortical microstructural changes along the Alzheimer's disease continuum. Alzheimer's and Dementia, 2018, 14, 340-351.	0.8	122
40	MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. Alzheimer's Research and Therapy, 2018, 10, 100.	6.2	64
41	The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. Alzheimer's Research and Therapy, 2018, 10, 64.	6.2	62
42	Obesity parameters, physical activity, and physical fitness are correlated with serum dipeptidyl peptidase IV activity in a healthy population. Heliyon, 2018, 4, e00627.	3.2	5
43	Increased CAIDE dementia risk, cognition, CSF biomarkers, and vascular burden in healthy adults. Neurology, 2018, 91, e217-e226.	1.1	22
44	Biomarcadores por tomografia por emisiÃ³n de positrones (PET): imagen de la patologÃa de Alzheimer y la neurodegeneraciÃ³n al servicio del diagnÃ³stico clÃnico. NeurologÃa, 2017, 32, 275-277.	0.7	5
45	Early Detection of Learning Difficulties when Confronted with Novel Information in Preclinical Alzheimerâ€™s Disease Stage 1. Journal of Alzheimer's Disease, 2017, 58, 855-870.	2.6	14
46	Tau/Î±â€synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study. Movement Disorders, 2017, 32, 1066-1073.	3.9	44
47	Beneficial effect of bilingualism on Alzheimer's disease CSF biomarkers and cognition. Neurobiology of Aging, 2017, 50, 144-151.	3.1	61
48	The Vascular Impairment of Cognition Classification Consensus Study. Alzheimer's and Dementia, 2017, 13, 624-633.	0.8	143
49	Cerebrospinal fluid mitochondrial DNA in the Alzheimer's disease continuum. Neurobiology of Aging, 2017, 53, 192.e1-192.e4.	3.1	24
50	Sex differences in the aging pattern of reninâ€“angiotensin system serum peptidases. Biology of Sex Differences, 2017, 8, 5.	4.1	89
51	[O3â€“10â€“03]: LONGITUDINAL CEREBROSPINAL FLUID BIOMARKER TRAJECTORIES ALONG THE ALZHEIMER'S DISEASE CONTINUUM: A MULTICENTRE EUROPEAN STUDY. Alzheimer's and Dementia, 2017, 13, P924.	0.8	3
52	Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype. Journal of Alzheimer's Disease, 2017, 57, 447-459.	2.6	26
53	Impact of APOE-É›4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults. Neurobiology of Aging, 2016, 38, 14-20.	3.1	37
54	Gray matter network disruptions and amyloid beta in cognitively normal adults. Neurobiology of Aging, 2016, 37, 154-160.	3.1	51

#	Article	IF	Citations
55	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. Alzheimer's and Dementia, 2016, 12, 154-163.	0.8	179
56	Projecting Burden of Dementia in Spain, 2010â€“2050: Impact of Modifying Risk Factors. Journal of Alzheimer's Disease, 2015, 48, 721-730.	2.6	33
57	Alzheimerâ€™s disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain, 2015, 138, 2701-2715.	7.6	109
58	Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. Neurology, 2015, 85, 626-633.	1.1	131
59	Fitting the epidemiology and neuropathology of the early stages of Alzheimerâ€™s disease to prevent dementia. Alzheimer's Research and Therapy, 2015, 7, 2.	6.2	19
60	Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: consensus proposal from the SEMNIM and SEN. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2015, 34, 303-313.	0.2	3
61	Automatic analysis of Categorical Verbal Fluency for Mild Cognitive impartment detection: A non-linear language independent approach. , 2015, , .		6
62	Phonation biomechanic analysis of Alzheimer×³s Disease cases. Neurocomputing, 2015, 167, 83-93.	5.9	8
63	Recomendaciones para la utilizaciÃ³n de biomarcadores de imagen PET en el proceso diagnÃ³stico de las enfermedades neurodegenerativas que cursan con demencia: documento de consenso SEMNIM y SEN. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2015, 34, 303-313.	0.0	16
64	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. Alzheimer's and Dementia, 2015, 11, 195.	0.8	56
65	Feature selection for spontaneous speech analysis to aid in Alzheimer's disease diagnosis: A fractal dimension approach. Computer Speech and Language, 2015, 30, 43-60.	4.3	41
66	On Automatic Diagnosis of Alzheimerâ€™s Disease Based on Spontaneous Speech Analysis and Emotional Temperature. Cognitive Computation, 2015, 7, 44-55.	5.2	97
67	Diet, cognition, and Alzheimerâ€™s disease: food for thought. European Journal of Nutrition, 2014, 53, 1-23.	3.9	216
68	Biomechanical characterization of phonation in Alzheimer's Disease. , 2014, , .		1
69	Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A Multicenter Study in Spain. Journal of Alzheimer's Disease, 2014, 39, 719-726.	2.6	53
70	Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimerâ€™s disease dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1394-1405.	6.4	42
71	Genetic risk score predicting accelerated progression from mild cognitive impairment to Alzheimerâ€™s disease. Journal of Neural Transmission, 2013, 120, 807-812.	2.8	63
72	On the Selection of Non-Invasive Methods Based on Speech Analysis Oriented to Automatic Alzheimer Disease Diagnosis. Sensors, 2013, 13, 6730-6745.	3.8	147

#	Article	IF	Citations
73	Several Direct and Calculated Biomarkers from the Amyloid-Î² Pool in Blood are Associated with an Increased Likelihood of Suffering from Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2013, 36, 211-219.	2.6	23
74	Feature Extraction Approach Based on Fractal Dimension for Spontaneous Speech Modelling Oriented to Alzheimer Disease Diagnosis. Lecture Notes in Computer Science, 2013, , 144-151.	1.3	4
75	Progression of Alzheimer Disease in Europe: Data from the European ICTUS Study. Current Alzheimer Research, 2012, 9, 902-912.	1.4	42
76	Paraneoplastic encephalitis presenting as pure word deafness in a patient with small cell lung cancer. Journal of Neurology, 2012, 259, 2755-2757.	3.6	7
77	Estrogen receptor alpha gene variants are associated with Alzheimer's disease. Neurobiology of Aging, 2012, 33, 198.e15-198.e24.	3.1	36
78	Reliable Measurements of theÎ²-Amyloid Pool in Blood Could Help in the Early Diagnosis of AD. International Journal of Alzheimer's Disease, 2012, 2012, 1-10.	2.0	52
79	The impact of silent vascular brain burden in cognitive impairment in Parkinsonâ€™s disease. European Journal of Neurology, 2012, 19, 1100-1107.	3.3	31
80	Alzheimerâ€™s Disease and Its Treatment With a Novel Transdermal Patch Therapy. primary care companion for CNS disorders, The, 2012, 14, .	0.6	1
81	The Effect of MAPT H1 and APOE Îµ4 on Transition from Mild Cognitive Impairment to Dementia. Journal of Alzheimer's Disease, 2011, 22, 1065-1071.	2.6	24
82	CALHM1 P86L Polymorphism is Associated with Late-Onset Alzheimer's Disease in a Recessive Model. Journal of Alzheimer's Disease, 2010, 20, 247-251.	2.6	38
83	Assessing physician attitudes and perceptions of Alzheimer's disease across Europe. Journal of Nutrition, Health and Aging, 2010, 14, 537-544.	3.3	17
84	Somatic mosaicism in a case of apparently sporadic Creutzfeldtâ€Jakob disease carrying a de novo D178N mutation in the PRNP gene. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 1283-1291.	1.7	33
85	Turning principles into practice in Alzheimerâ€™s disease. International Journal of Clinical Practice, 2010, 64, 1198-1209.	1.7	5
86	Brain Perfusion Correlates of Visuoperceptual Deficits in Mild Cognitive Impairment and Mild Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 21, 557-567.	2.6	30
87	Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. Neurobiology of Aging, 2010, 31, 725-731.	3.1	196
88	Drug Profile: Transdermal Rivastigmine Patch in the Treatment of Alzheimer Disease. CNS Neuroscience and Therapeutics, 2010, 16, 246-253.	3.9	25
89	Ecological assessment of executive functions in mild cognitive impairment and mild Alzheimerâ€™s disease. Journal of the International Neuropsychological Society, 2009, 15, 751-757.	1.8	59
90	5â€²-upstream variants of CRHR1 and MAPT genes associated with age at onset in progressive supranuclear palsy and cortical basal degeneration. Neurobiology of Disease, 2009, 33, 164-170.	4.4	24

#	Article	IF	Citations
91	GAB2 gene does not modify the risk of Alzheimer's disease in Spanish APOE 4 carriers. Journal of Nutrition, Health and Aging, 2009, 13, 214-219.	3.3	31
92	Ubiquitin associated protein 1 is a risk factor for frontotemporal lobar degeneration. Neurobiology of Aging, 2009, 30, 656-665.	3.1	33
93	GOLPH2 Gene Markers are Not Associated with Alzheimer's Disease in a Sample of the Spanish Population. Journal of Alzheimer's Disease, 2009, 18, 751-754.	2.6	7
94	Multi-Center Comparison of Medial Temporal Atrophy in Patients with Alzheimer’s Disease – Data from the ICTUS Study. Dementia and Geriatric Cognitive Disorders, 2008, 26, 314-322.	1.5	8
95	Genes related to iron metabolism and susceptibility to Alzheimer's disease in Basque population. Neurobiology of Aging, 2007, 28, 1941-1943.	3.1	30
96	The corticobasal degeneration syndrome overlaps progressive aphasia and frontotemporal dementia. Neurology, 2000, 55, 1368-1375.	1.1	306
97	Prevalence and Disease Associations of Argyrophilic Grains of Braak. Journal of Neuropathology and Experimental Neurology, 1997, 56, 157-164.	1.7	91
98	Prevalence of Alzheimer's Disease and Other Dementing Disorders in Pamplona, Spain. Neuroepidemiology, 1995, 14, 155-164.	2.3	56